<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118909</url>
  </required_header>
  <id_info>
    <org_study_id>MEI-007</org_study_id>
    <nct_id>NCT02118909</nct_id>
  </id_info>
  <brief_title>Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects</brief_title>
  <official_title>A Two-Part Study to Evaluate the Effect of CYP3A4 Inhibition (Itraconazole-Part 1) and CYP1A2 Inhibition (Ciprofloxacin - Part 2) on the Single-Dose Pharmacokinetics of Pracinostat in Healthy Nonsmoking Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a 2-part, open-label study to assess the effect of pracinostat with&#xD;
      itraconazole (part 1) and pracinostat with ciprofloxacin (part 2) on the bioavailability of&#xD;
      pracinostat. Secondarily to evaluate the safety and tolerability of pracinostat administered&#xD;
      with itraconazole or ciprofloxacin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration Cmax in healthy nonsmoking subjects given a single-dose of pracinostat</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours</time_frame>
    <description>Plasma PK parameter Cmax to describe bioavailability of pracinostat</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as a measure of safety and tolerability of single-dose pracinostat when administered with itraconazole or with ciprofloxacin in healthy nonsmoking adult subjects.</measure>
    <time_frame>1 month</time_frame>
    <description>Safety will be monitored through physical examinations, vital sign measurements, electrocardiograms, adverse events, and clinical laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma PK concentration Area Under the Curve (AUC)AUC 0-t, AUC 0-inf in healthy nonsmoking subjects given a single dose of pracinostat</measure>
    <time_frame>pre-dose, 0.25, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours</time_frame>
    <description>Plasma PK parameter AUC 0-t, AUC 0-inf for pracinostat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Non-smokers</condition>
  <arm_group>
    <arm_group_label>Part 1 (Pracinostat + Itraconazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose pracinostat and itraconazole dosing every day for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Pracinostat + Ciprofloxacin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose pracinostat and ciprofloxacin 2 times a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pracinostat</intervention_name>
    <arm_group_label>Part 1 (Pracinostat + Itraconazole)</arm_group_label>
    <arm_group_label>Part 2 (Pracinostat + Ciprofloxacin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <arm_group_label>Part 2 (Pracinostat + Ciprofloxacin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <arm_group_label>Part 1 (Pracinostat + Itraconazole)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer&#xD;
&#xD;
          -  Continuous nonsmoker who has not used nicotine-containing products for at least 3&#xD;
             months prior to the first dose&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or ECGs, as deemed by the PI.&#xD;
&#xD;
          -  Female subjects must be of non-childbearing potential and must have undergone&#xD;
             sterilization procedures at least 6 months prior to the first dose or be&#xD;
             postmenopausal with amenorrhea for at least 1 year prior to the first dose and&#xD;
             follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.&#xD;
&#xD;
          -  A non vasectomized, male subject must agree to use a condom with spermicide or abstain&#xD;
             from sexual intercourse during the study until 90 days beyond the last dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Understands the study procedures in the informed consent form (ICF), and be willing&#xD;
             and able to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated or has significant emotional problems at&#xD;
             the time of screening visit or expected during the conduct of the study.&#xD;
&#xD;
          -  History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the PI.&#xD;
&#xD;
          -  History of any illness that, in the opinion of the PI, might confound the results of&#xD;
             the study or poses an additional risk to the subject by their participation in the&#xD;
             study.&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within the past 2 years prior to&#xD;
             screening.&#xD;
&#xD;
          -  History or presence of hypersensitivity or idiosyncratic reaction to the study&#xD;
             medication or related compounds.&#xD;
&#xD;
          -  History of prolonged QT syndrome or require any current medications which may prolong&#xD;
             QTc.&#xD;
&#xD;
          -  History or presence of:&#xD;
&#xD;
               -  myasthenia gravis;&#xD;
&#xD;
               -  convulsions.&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating.&#xD;
&#xD;
          -  Positive urine cotinine, drug and alcohol results at screening or check-in.&#xD;
&#xD;
          -  Positive results at screening for HIV, HBsAg or HCV.&#xD;
&#xD;
          -  Seated blood pressure is less than 90/40 mgHg or greater than 140/90 mmHg at&#xD;
             screening.&#xD;
&#xD;
          -  Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
&#xD;
          -  QTcF interval, is &gt;430 msec (males) or &gt;450 msec (females) or deemed clinical abnormal&#xD;
             by the PI at screening or prior to dosing.&#xD;
&#xD;
          -  Unable to refrain from or anticipates the use of:&#xD;
&#xD;
               -  Any drug, including prescription and non-prescription medications, tobacco,&#xD;
                  antacids, herbal remedies, or vitamin supplements beginning approximately 14 days&#xD;
                  prior to the first dose of study medication and throughout the study. Hormone&#xD;
                  replacement therapy will be allowed if postmenopausal females are on a stable&#xD;
                  treatment for at least 1 month prior to dosing on Day 1 of Period 1.&#xD;
                  Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study.&#xD;
&#xD;
               -  Any drugs known to be significant inducers of CYP enzymes, including St. John's&#xD;
                  Wort, for 28 days prior to the first dose of study medication and throughout the&#xD;
                  study. Appropriate sources will be consulted by the PI or designee to confirm&#xD;
                  lack of PK/pharmacodynamics interaction with study medication.&#xD;
&#xD;
          -  Have been on a diet incompatible with the on-study diet, in the opinion of the PI,&#xD;
             within the 28 days prior to the first dose of study medication(s), and throughout the&#xD;
             study.&#xD;
&#xD;
          -  Hemoglobin, platelet count or absolute neutrophils below the lower limit of normal at&#xD;
             screening.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) above upper limit&#xD;
             of normal at screening.&#xD;
&#xD;
          -  Donation of blood or significant blood loss within 56 days prior to the first dose of&#xD;
             study medication.&#xD;
&#xD;
          -  Participation in another clinical trial within 28 days prior to the first dose of&#xD;
             study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry E O'Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>67296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.meipharma.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

